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Abstract
Background: Some industrial hygiene studies have assessed occupational exposure to antineoplastic drugs; other
epidemiological investigations have detected various toxicological effects in exposure groups labeled with the job
title. In no research has the same population been studied both environmentally and epidemiologically. The
protocol of the epidemiological study presented here uses an integrated environmental and biological monitoring
approach. The aim is to assess in hospital nurses preparing and/or administering therapy to cancer patients the
current level of occupational exposure to antineoplastic drugs, DNA and chromosome damage as cancer predictive
effects, and the association between the two.
Methods/Design: About 80 healthy non-smoking female nurses, who job it is to prepare or handle antineoplastic
drugs, and a reference group of about 80 healthy non-smoking female nurses not occupationally exposed to
chemicals will be examined simultaneously in a cross-sectional study. All the workers will be recruited from five
hospitals in northern and central Italy after their informed consent has been obtained.
Evaluation of surface contamination and dermal exposure to antineoplastic drugs will be assessed by determining
cyclophosphamide on selected surfaces (wipes) and on the exposed nurses’ clothes (pads). The concentration of
unmetabolized cyclophosphamide as a biomarker of internal dose will be measured in end-shift urine samples
from exposed nurses.
Biomarkers of effect and susceptibility will be assessed in exposed and unexposed nurses: urinary concentration of
8-hydroxy-2-deoxyguanosine; DNA damage detected using the single-cell microgel electrophoresis (comet) assay in
peripheral white blood cells; micronuclei and chromosome aberrations in peripheral blood lymphocytes. Genetic
polymorphisms for enzymes involved in metabolic detoxification (i.e. glutathione S-transferases) will also be
analysed.
Using standardized questionnaires, occupational exposure will be determined in exposed nurses only, whereas
potential confounders (medicine consumption, lifestyle habits, diet and other non-occupational exposures) will be
assessed in both groups of hospital workers.
Statistical analysis will be performed to ascertain the association between occupational exposure to antineoplastic
drugs and biomarkers of DNA and chromosome damage, after taking into account the effects of individual genetic
susceptibility, and the presence of confounding exposures.
Discussion: The findings of the study will be useful in updating prevention procedures for handling antineoplastic
drugs.
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Background
The occupational risk of environmental contamination
during the storage, reconstitution, administration of
antineoplastic drugs and the elimination of residues is
well documented [1-4]. The chemical and physical prop-
erties of the drug, the quantity administered, the avail-
ability of personal and collective protection devices and
the worker’s skill determine the level of antiblastic
contamination.
Several studies carried out at hospital units have
shown detectable levels of cytotoxic agents in the air
[5-7], on surfaces [8-15], on gloves [8,14], and on differ-
ent parts of the body [7,8,16]. Biological monitoring
methods have been developed to detect occupational
exposure to antineoplastic agents [17]. The presence of
these drugs in the urine of hospital personnel has been
widely studied [7,9,18-20]. This has lead several organi-
zations to develop guidelines or recommendations with
the aim to improve safety during the handling of anti-
neoplastic drugs and reduce risk of contamination in
the workplace [21-23]. Based on these findings, guide-
lines have been also published in Italy [24].
Many anticancer agents have the potential to cause
genetic alterations, which may lead to the development
of cancer if they occur in proto-oncogenes or tumour-
suppressor genes, which are involved in controlling cell
growth or differentiation [25]. Accordingly, several anti-
neoplastic drugs have been classified by the Interna-
tional Agency of Research on Cancer (IARC), on the
basis of epidemiological reports, animal carcinogenicity
data, as well as the outcomes of in vitro genotoxicity
studies, as definite (Group 1), probable (Group 2A) or
possible (Group 2B) human carcinogens [26-29].
Although health care workers are exposed to much
lower doses than cancer patients are, low-dose exposure
over long periods can have long-term health effects.
Several epidemiological studies have been conducted
investigating the cancer risks of nurses exposed to anti-
neoplastic drugs. Increased risks for leukaemia and
breast cancer were reported by Skov et al. [30] and
Gunnarsdottir et al. [31]. In a more recent research arti-
cle, Ratner et al. [32] performed a cohort study among
over 56,000 Canadian female nurses from British
Columbia and concluded that subjects potentially
exposed to antineoplastic drugs through their employ-
ment had an elevated risk of breast and rectal cancer.
Following environmental monitoring studies on con-
tamination of workplaces from antineoplastic drugs, sev-
eral biological monitoring studies have been performed.
A number of studies indicate that antineoplastic drugs
may cause increased genotoxic effects in pharmacists
and nurses exposed in the workplace.
Undeger et al. [33] reported a significantly higher fre-
quency of DNA damage - analysed using the alkaline
single cell gel electrophoresis technique (comet assay) -
in lymphocytes of nurses handling antiblastic drugs
compared to unexposed controls; the DNA damage was,
however, found to be significantly lower in nurses using
compulsory personal protection equipment during their
work. 8-hydroxy-2’-deoxyguanosine (8OHdG) - pre-
sumed to be an expression of oxidative damage to DNA
- has never been used in assessing the mutagenic risk of
occupational exposure to antineoplastic drugs.
Chromosome aberration (CA) frequencies in patients
undergoing chemotherapy were significantly higher than
in controls [34-37]. Increased CA frequencies have also
been found in hospital personnel handling cytotoxic
drugs [18,38-43]. Negative findings have also been
reported, however [44-47]. In hospitals where nurses
used inadequate safety cabinets when handling cyto-
statics, significantly elevated levels of CAs (as well as sis-
ter chromatid exchanges, SCEs, and unscheduled DNA-
repair synthesis) were detected by Jakab et al. [48].
According to Kevekordes et al. [49], a malfunctioning
safety hood resulted in a higher frequency of micronu-
clei (MN) and SCE in exposed nurses compared to
matched controls. Kasuba et al. [50] found that the
length of handling cytostatic drugs increased the fre-
quency of MN, whereas no statistically significant differ-
ence was observed for SCE. In hospital pharmacy
personnel adopting high standards of safety, Pilger et al.
[51] observed that frequencies of MN and SCE were
similar to those of controls, whereas small increases in
these genetic end-points were found in accidental con-
tamination events. Anwar et al. [43] found statistically
significant increases in both CAs and MN in nurses
handling cytostatic drugs. Hessel et al. [52] reported no
association between antiblastic drugs in urine and MN
frequency in lymphocytes of exposed hospital workers.
Lastly, Maluf & Erdtmann [53], when comparing phar-
macists and nurses exposed to antineoplastic drugs with
unexposed controls, found no statistical difference for
MN and dicentric bridge frequency, whereas the mean
value of DNA migration detected by comet assay was
significantly higher in the exposed group compared to
the controls.
Several studies showed the influence of metabolic and
DNA repair polymorphisms on biological indicators of
genotoxic risk (urinary metabolites, protein and DNA
adducts, citogenetic tests), which are commonly used in
the biomonitoring of occupational exposure to antineo-
plastic agents [54]. There are however few studies on
the influence of genetic polymorphisms of enzymes
involved in DNA damage induced by occupational expo-
sure to antineoplastic drugs [55,56].
In conclusion, some chemical studies have assessed
occupational exposure to antineoplastic drugs, and some
epidemiological investigations have detected various
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toxicologic effects in groups of exposed workers. To our
knowledge, only very few researches have studied the
same population by simultaneous assessment of expo-
sure, biologic effects and genetic susceptibility [57].
The protocol of this molecular epidemiology study
therefore presents an integrated chemical and biotoxico-
logical approach for environmental and biological moni-
toring of exposure and cancer risks which will be
implemented in a large number of healthy non-smoking
female hospital nurses. This approach is based on moni-
toring procedures reported on the Italian guidelines [24]
which includes, beside methods for preventing exposure
to antineoplastic drugs, also monitoring recommenda-
tions. In particular, the guidelines provides guidance on
the control of antineoplastic drug contaminations on
surfaces and clothes by environmental monitoring (wipe
and pad tests, respectively) and on the control of expo-
sure by biological monitoring (concentrations of anti-
neoplastic drugs in body fluids, usually urine), with both
contamination and exposure depending on working
practices and the frequency and adequacy of decontami-
nation procedures. In this context, the advantage of bio-
logical monitoring is being able to measure the total
uptake of antineoplastic drugs by all routes of exposure,
however, testing is generally limited to one or very few
agents that are considered as model compounds. In this
study, monitoring of genotoxic risks we will performed
by combining environmental and biological monitoring
as above, with procedures for biological effect monitor-
ing (urinary 8OHdG, DNA strand breakage and cytoge-
netic abnormalities in lymphocytes) as well as genetic
susceptibility monitoring (metabolic polymorphisms).
Study objectives
The aim of this study is to assess:
• the level of exposure to antineoplastic drugs (con-
centrations of substances in the working environment
and on clothes; levels of biomarkers of exposure in end-
shift urine) in nurses preparing and administering anti-
neoplastic drugs;
• the profile of DNA and chromosome damage (cyto-
genetic and DNA primary alterations) and genetic poly-
morphisms in the same nurses preparing and/or
administering therapy to cancer patients and in a con-
trol group of unexposed nurses;
• the association between exposure and genetic
damage, taking into account the confounding effects of
non-occupational exposures and the modulating effects
of genetic polymorphisms.
Among the several biotoxicological tests that will be
performed, the frequency of micronuclei (MN) and
chromosome aberrations (CA) in peripheral lymphocytes
are recognized to be predictors of cancer risks in human
populations [58,59].
Methods/Design
The proposed epidemiological study will be carried out
following the integrated environmental and biological
monitoring approach shown in Figure 1.
Population recruitment
The study will be conducted on about 80 healthy non-
smoking female nurses whose job it is to prepare and
administer antineoplastic drugs. Workers will be
recruited on a voluntary basis from five hospital depart-
ments in northern and central Italy. A reference group
of about 80 healthy non-smoking female nurses - work-
ing in the same hospitals but not occupationally exposed
to antineoplastic drugs, comparable for age and lifestyle
habits - will be sampled and examined in parallel with
the exposed group. Exclusion criteria will be male gen-
der, active smoking, and radiography, radiotherapy or
chemotherapy in the past 12 months.
An informed consent form will be signed by each
worker included in the study.
Sample collection
Work-shift urine samples will be collected from the
workers in the investigated workplaces. Urine will be
continuously collected 4 hours after the beginning until
the end of the work-shift. During the same sampling
session, end-shift blood samples will be collected taken
by venipuncture and collected in heparinized or lithium
EDTA vacuum tubes, for cytogenetic analyses or geno-
typing, respectively [60-62].
Questionnaires
A questionnaire regarding the work environment will
be designed to gather information from the ward sister
on key characteristics of each hospital ward, namely:
details of the preparation area (hood: type, discharge
type, coverage plan, inlet and outlet filters, filters
replacement and cleaning procedures), as well as con-
ditions in the preparation and administration areas
(appropriate space, exclusive use, access restrictions;
presence of warning signs, dressing room, sinks,
eyewash, shower; adequate lighting and ventilation,
microclimate conditions; waterproof uniform intact
floor and walls).
Trained interviewers will collect information from
each subject by means of three other standardized ques-
tionnaires (A, B, and C).
Questionnaire A, which will be administered to both
exposed and unexposed nurses, investigate personal
details (age, height and weight), previous and present
diseases, lifestyle habits (diet, passive smoking, alcohol
and medicine consumption, physical activity and other
leisure activities), and non-occupational exposures to
mutagenic and carcinogenic agents, such as polycyclic
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aromatic hydrocarbons (PAH) present in diet (weekly
consumption of charcoaled and/or smoked meat),
indoor (use of wood or coal to heat the home) and out-
door environment (residence close to intense traffic
and/or factories) [61,63].
Questionnaires B and C, which will be administered to
exposed nurses only, investigate work experience and
occupational exposures. Emphasis will be placed on
gathering the following information:
• hospital ward, years of service, length of exposure
for each task (preparation or administration of cytostatic
drugs, patient care, waste disposal) performed during a
typical work-shift;
• antineoplastic drug exposure: names of cytostatics
most frequently handled in the previous 12 months
(questionnaire B); names and quantities of cytostatics
handled during the last two workshifts (questionnaire C);
• safety measures adopted by each worker (use of per-
sonal protection equipment, PPE; hand washing fre-
quency; other).
Environmental monitoring of exposure
Chemical analysis of the environmental samples will be
carried out by determining the concentration of cyclo-
phosphamide (CP), the marker of exposure to antineo-
plastic drugs according to established guidelines [24].
CP concentration will be determined in the work envir-
onment by using two techniques:
• surface removal technique (wipe-test);
• pad technique, to evaluate the contamination of
exposed nurses’ clothes.
Wipe test
The wipe sampling procedure will be performed accord-
ing to the method of Sessink et al. [64], modified [65].
Monitoring occupational
genotoxic risks
Environmental
monitoring
Compound
selective
Oxidative
damage
Metabolic
polymorphisms
Chromosomal
damage
DNA damage
- CP - 8OHdG -
-
GSTM1
GSTT1
- MN
- CA
Urine Urine Genes
Lymphocytes
- Comet assay
- Comet/Endo
assay
- Comet/Ara-C
assay
Leukocytes
Lymphocytes
Biological
monitoring
Biological effect
monitoring
Genetic susceptibility
monitoring
Surface
contamination
- CP
Wipes
Clothing
contamination
- CP
Pads
Figure 1 Occupational genotoxic risks in healthcare workers handling antineoplastic drugs: scheme of the study protocol. CP:
cyclophosphamide; 8OHdG: 8-hydroxy-2’-deoxyguanosine; MN: micronuclei; CA: chromosome aberrations; GST: glutathione-S-transferase.
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The technique involves cleaning a standard surface mea-
suring 15 × 15 cm (225 cm2) thoroughly using a set of
folded wipes (non-woven disposable material) wetted
with 2 ml of 0.03 M NaOH solution. The standard sam-
pling sites will be located on the hood surface (prepara-
tion site) or the drip surface (administration site). Blank
wipes will also be tested. New gloves will be used for
each collected wipe sample to prevent cross-contamina-
tion. The wipes will be put in test-tubes and transferred
to the laboratory. Subsequently, 18 ml of 0.03 M NaOH
solution will be added. The samples will be stirred for
10 minutes, sonicated for 30 minutes, centrifuged at
3000 rpm for 20 minutes and stored at -20°C until
analysis.
The analysis will be carried out with GC-MS/MS.
Briefly, a 1 ml of sample will be added with 100 μl of
ifosfamide (IS) as internal standard. The solution will be
put in a cartridge containing diatomaceous heart and
the analytes eluted with 5 ml of ethyl acetate (twice).
Organic layers will be combined and dried in a vacuum
centrifuge. The residue will be dissolved in 100 μl of
ethyl acetate and the CP and IS will be derivatized by
adding 50 μl of trichloroacetic anhydride at 70°C for 30
minutes. The solvent will be evaporated in a vacuum
centrifuge, and the residue will be dissolved in 50 μl of
toluene and analysed in GC-MS/MS.
Pad test
The pad technique - widely used for monitoring xeno-
biotics [5] - will be used to evaluate contamination of
clothes of nurses exposed to antineoplastic drugs. A pad
of non-woven disposable material will be applied to
clothes of the left forearm (non-dominant arm) of each
subject during the working shift. The pad will be dam-
pened with 1 ml of 0.03 M NaOH solution. The pads
will be recovered at the end of the shift, placed in test-
tubes and transferred to the laboratory, where they will
be treated according to the procedure used for the
wipe-tests.
On the whole, 1 wipe test (hood surface) and 1 pad
test (left forearm) will be performed for each worker
preparing antineoplastic drugs; 1 wipe test (drip surface)
and 1 pad test (left forearm) will be carried out for each
worker administering the drugs.
Biological monitoring of exposure
To allow a better evaluation of exposure, a biomarker of
internal dose (CP) will be measured in end-shift urine
samples using an analytical method developed by Bar-
bieri et al. [66]. Urine samples will be collected from the
exposed workers during days that CP is handled.
The analysis will be performed by liquid chromatogra-
phy coupled with a triple-quadrupole mass spectrometer
equipped with an electrospray source (LC-ESI-MS/MS)
after urine sample purification and concentration using
solid phase extraction (SPE). Mass spectrometric detec-
tion increases sensitivity, and multiple-reaction-monitor-
ing (MRM) acquisition mode leads to high specificity (i.
e. the limit of detection is 0.04 μg/l urine for CP).
Another aim of the study will be also to improve the
sensitivity of the above method using a micro-HPLC,
with lower flows (10 μl/min versus 200 μl/min for con-
ventional HPLC) and smaller sample volumes (0.5 μl
versus 20 μl).
Biomarkers of DNA and chromosome damage
The biomarkers of DNA damage will be assessed in
exposed and unexposed nurses.
Urinary concentration of 8OHdG
T he determination of urinary 8-hydroxy-2-deoxyguano-
sine (8OHdG) will be determined in both study groups,
i.e. workers exposed and not exposed to antineoplastic
drugs. The method, validated by Sabatini et al. [67], is
based on high-performance capillary liquid chromato-
graphy coupled with an electrospray source with tandem
mass spectrometric detection (micro-HPLC-ESI-MS/
MS). Urine samples will be collected and extracted
using Isolute Env+ SPE cartridges, and 0.5 μl of this
extract will undergo micro-HPLC-ESI-MS/MS. MS/MS
analysis will be conducted in positive ion mode and
acquisition will be performed in MRM mode, selectively
monitoring the typical transition of 8OHdG.
Comet Assay
To assess primary DNA damage under alkaline condi-
tions, the single-cell microgel electrophoresis (comet)
assay [68,69] will be performed on peripheral blood leu-
kocytes of exposed and control nurses [60,70-72]. For
slide preparation, 10 μl aliquots of heparinized blood
will be mixed with 100 μl low-melting-point agarose
(0.7% in PBS) and layered onto pre-treated conventional
slides. After overnight lysis (+4°C) in alkaline buffer (pH
10) of cellular and nuclear membranes, the slides will be
placed in a horizontal electrophoresis box, allowed to
unwind for 20 min in an electrophoretic alkaline buffer
(pH > 13) and then subjected to electrophoresis (+4°C)
for 20 min by applying an electric field of 1 V/cm and
adjusting the current to 300 mA. Lastly, the microgels
will be neutralized and stained with ethidium bromide.
To evaluate DNA damage, the slides will be examined
using an epi-fluorescence microscope equipped with a
high-sensitivity CCD (charge-coupled device) camera
connected to a computerized image analysis system.
Computerized imaging will be performed on coded
slides using dedicated software which estimates damage
parameters (i.e. tail length, tail intensity and tail
moment) by comet profile [73]. Two hundred cells will
be analysed for each subject (100 cells/slide, 2 slides per
subject). Since the three research units examining DNA
damage will use different computerized analysis systems,
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intercalibration tests will be performed to standardize
the procedures used for DNA migration evaluation. For
this purpose, the extent of DNA migration will also be
evaluated by “visual scoring” based on visual classifica-
tion of DNA damage.
Comet/Endo-III assay (DNA oxidative damage)
DNA oxidative damage will be evaluated in peripheral
blood lymphocytes with a modification of the standard
comet assay using enzymes of the excision repair system
[74]. Endonuclease III (Endo-III) recognizes and cuts
oxidized bases, mostly pyrimidines [75,76]. When this
enzyme nicks DNA at sites of oxidatively damaged
nucleotides, it creates single-strand breaks(SSB) detect-
able using the alkaline comet assay. For slide prepara-
tion, freshly collected white blood cells will be included
in agarose microgels as described for the standard
comet assay. After the lysis step, the microgels will be
incubated with Endo-III for 60 min at 37°C. The slides
will undergo alkaline electrophoresis (30 min unwinding
and 20 min electrophoresis) and then stained as
described for the standard comet assay. To evaluate
DNA damage, the slides will be examined as described
above for the standard procedure of the comet assay.
Comet/Ara-C assay
A modified protocol that uses a DNA repair inhibitor
has been proposed as a means for increasing the sensi-
tivity of the assay [77]. In particular, lymphocyte incuba-
tion with cytosine arabinoside (Ara-C) inhibits DNA re-
synthesis during nucleotide excision repair and under
standard experimental conditions transforms ‘cryptic’
lesions into SSB detectable with the alkaline comet
assay. The evaluation of DNA damage to cells treated
with Ara-C will be performed on peripheral blood lym-
phocytes isolated from whole blood samples using poly-
sucrose density-gradient. The lymphocytes will be re-
suspended in RPMI-1640 medium and cultured for 16 h
in the presence or the absence of Ara-C (1 μg/ml) [78].
At the end of the culture time the cells will be washed
and harvested by centrifugation, and the pellets will be
mixed with low-melting-point agarose, subjected to
alkaline lysis and electrophoresis, and stained and ana-
lysed as described for the standard comet assay.
Cytokinesis-block micronucleus test
All the subjects (exposed and controls) will be tested for
the presence of MN in lymphocytes. Cell cultures will
be set up by adding 0.3 ml of whole blood to 4.7 ml of
RPMI-1640 medium supplemented with 20% foetal calf
serum, 2 mM L-glutamine, 2% phytohaemoagglutinin
and penicillin-streptomycin (100 IU/ml e 100 μg/ml,
respectively). Whole blood cultures will be incubated for
72 h at 37°C, 5% CO2 [79]. To have binucleated cells,
cytochalasin B (final concentration 3 μg/ml) will be
added after 44 h [80]. The cells will then be collected by
centrifugation, re-suspended in a pre-warmed hypotonic
solution (75 mM KCl) for 15 min at 37°C and fixed in
acetic acid - methanol (1:5 v:v). Air-dried preparations
will be stained with 4% Giemsa. For cytogenetic analysis,
a total of 1000 binucleated lymphocytes with preserved
cytoplasm will be scored for each subject. MN evalua-
tion will be based on standard criteria [81].
Chromosome aberration test
The entire population of enrolled subjects will also be
tested for the presence of CA. Cell cultures will be set
up by adding 0.5 ml of whole blood to 4.5 ml of
RPMI-1640 medium supplemented with 10% foetal calf
serum, 2% phytohaemoagglutinin and 1.5% penicillin-
streptomycin. Whole blood will be cultured at 37°C,
5% CO2, following 90 minutes treatment with 0.2 μg/
ml colcemid. 5-Bromodeoxyuridine will be added at a
final concentration of 10 μg/ml. Cultures will be fixed
at 48 h according to standard protocol [82]. Air-dried
metaphase spreads will be stained according to the
conventional unbanded Giemsa method. For cytoge-
netic analysis, an average of 100 well-spread meta-
phases per subject will be examined by optical
microscopy. The analysis of CA will be performed only
on cells with 46 chromosomes (+/- 1). CA will classi-
fied on the basis of standard criteria [83]. Both chro-
mosome- and chromatid-type aberrations will be
scored. Chromosome and chromatid breaks will be dis-
tinguished from gaps according to their break size and
morphology.
Biomarkers of genetic polymorphisms
Genetic polymorphisms for enzymes involved in meta-
bolic detoxification (GSTM1 and GSTT1) will be ana-
lysed in exposed and unexposed nurses.
Genotype analysis
DNA from peripheral blood leucocyte (PBL) pellets will
be isolated with a Promega Wizard genomic DNA puri-
fication kit (Promega, Italy). As described previously
[84], the procedure will provide DNA free of RNA and
protein contamination. A multiplex PCR method will be
used to detect the presence or absence of the GSTM1
and GSTT1 genes, according to the protocol described
previously [85]. This PCR method presents both
GSTM1- and GSTT1-specific primer pairs in the same
amplification mixture and includes a third primer pair
for b-globin as an internal positive PCR control. The
GSTT1 (480 bp), b-globin (285 bp), and GSTM1 (215
bp) amplification products will be resolved in an ethi-
dium bromide-stained 2% agarose gel. The absence of
the GSTM1- or GSTT1-specific fragment indicates the
corresponding null genotype (*0/*0), whereas the b-glo-
bin-specific fragment confirms the presence of amplifi-
able DNA in the reaction mixture. Quality control
measures will be adopted for validation of results using
RT-PCR and blind repeat of 10% of samples.
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Statistical analysis
Statistical analysis will be performed to determine the
association between occupational exposure to antineo-
plastic drugs (evaluated by environmental and biological
monitoring) and biomarkers of DNA and chromosome
damage, taking into consideration the effect of genetic
polymorphisms, the safety procedures adopted, and con-
founding exposures of non-occupational origin.
The required sample size for the comparison of means
from two independent samples was estimated assuming:
• the means and standard deviations reported in litera-
ture for DNA damage detected using the single-cell
microgel electrophoresis (comet) assay in peripheral
white blood cells, MN and CA in peripheral blood
lymphocytes;
• a type I error rate of 0.05 and a power of 0.80.
Using the module “sampsi” of STATA 10 statistical
software, the minimum sample size was of 47 exposed
and 47 control nurses. The actual sample will be
enlarged to include 80 individuals in each sample, to
take also account of the number of predictors in the
multiple regression analysis.
Ethical approval
The study protocol has been firstly approved by the
Ethics Committee of Health Institutions of Umbria
Region (CEAS, Comitato Etico delle Aziende Sanitarie
della Regione Umbria), Perugia and then by the other
regional ethics committees (Comitato Etico dell’Azienda
Ospedaliero-Universitaria di Bologna, Policlinico San-
t’Orsola-Malpighi, Bologna; CEIOC, Comitato Etico Isti-
tuzioni Ospedaliere Cattoliche, Brescia; Comitato di
Etica dell’Università degli Studi di Parma, Parma).
Discussion
In a cross-sectional design such as ours, the prevalence
of a disease is measured in relation to its determinants.
Prevalence is a composite parameter, which depends on
the incidence rate, the rate of cure, the fatality rate, and
the duration of the disease. In addition, in studies of
occupational epidemiology, health-selective turnover
may further distort the information contained in the
prevalence rate.
A follow-up of the study base - an incidence study - is
better suited to solving etiologic problems than a cross-
sectional one. The incidence of a disease is usually more
informative than its prevalence, and incidence studies
require a longitudinal design in which exposure and
outcome are measured at different points in time.
Although cross-sectional designs have no time dimen-
sion, they can sometimes provide etiologic information.
One example is the study of diseases with short or no
latency, such as respiratory symptoms caused by irritant
gases.
This study comprises short-term risk factors (names
and quantities of cytostatics handled during the last two
workshifts, collected on questionnaire C; CP in urine)
and short-term response indicators (DNA strand breaks
in polymorphonuclear leukocytes which have a lifetime
of few hours to few days, as well as urinary 8OHdG). It
should be noted that questionnaire C will be filled in
the same day on which urine (for CP concentration)
and blood (for comet assay) will be collected. We will
therefore be able to determine whether there is an etio-
logical association between occupational exposure to
cytostatics and DNA damage.
This study also includes medium-term changes (cyto-
genetic abnormalities in lymphocytes which have a life-
time of weeks to years). AC and MN are of particular
importance for prevention, since recent epidemiological
studies have demonstrated the predictive value of carci-
nogenic risks from these two biomarkers [58,59].
The difference between exposed and unexposed
nurses with regard to changes in short-term response
(comet assay) could be less evident than that concerning
medium-term effects (AC and MN). These results
would indicate overall working conditions less satisfac-
tory or safe in the past than in current conditions.
Any association between CP contamination and the
use of PPE and number of preparations/day could
potentially suggest useful information for prevention: an
increase in health education if contamination is found
to increase with relaxed rules of prevention, or a
decrease in the workload if the number of applications
is found to conflict with the level of prevention.
Both short-term and medium-term indicators of DNA
damage are non-specific responses which depend on sev-
eral risk factors of occupational and non-occupational
origin. In order to prevent confounding, it has been
decided to focus on one category of nurses, only female
nurses declaring themselves to be long-life non-smokers.
There are also other restrictions (see exclusion criteria in
Methods). This choice requires the number of hospitals
involved to be increased to 5 in order to achieve a sample
size with sufficient statistical power. Restriction alone is a
weak method for controlling confounding, and this can
only be achieved by proper statistical analysis. Therefore,
in order to control for non-occupational confounders, we
have devised questionnaire A to gain information on a
large number of potential risk factors.
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